Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Early communication of ongoing safety review
The US FDA has issued an early communication about the ongoing review of new safety data for bisphosphanate medicines such as { drug_name }. The communication was issued by the FDA after it received reports of abnormal heart rhythms that may have been associated with bisphosphanate use. Upon initial review, it is unclear how this data should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time. For more information, please visit: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070303.htm
Learn More

Early communication of ongoing safety review
The US FDA has issued an early communication about the ongoing review of new safety data for bisphosphanate medicines such as { drug_name }. The communication was issued by the FDA after it received reports of abnormal heart rhythms that may have been associated with bisphosphanate use. Upon initial review, it is unclear how this data should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time. For more information, please visit: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070303.htm
Learn More

Back to Consumer Med Safety